{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:11145"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:11145","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Biochemical markers and combination testing for the diagnosis of ovarian cancer in women with symptoms or signs suspicious of ovarian cancer","abstract":"Ovarian cancer (OC) has the highest mortality of all gynaecological cancers. A significant contributing factor to the high mortality in OC is delayed diagnosis. Currently, there is no consensus regarding the best test for early diagnosis. A review of existing systematic reviews about symptoms, biochemical markers and US test used alone or in combination for the diagnosis of OC in symptomatic women demonstrated that existing reviews were variable in quality, applicability and limited by poor reporting. I attempted to address these deficiencies in two reviews on the accuracy of biomarkers alone and symptoms, biomarkers or US in combination for the diagnosis of OC in symptomatic women in generalist settings in pre and postmenopausal women separately. My thesis finds key methodological issues, e.g., literature is not applicable to generalist settings as studies included women typical of tertiary healthcare settings, some studies excluded borderline tumours which inflates estimates of sensitivity, important differences exist in test performance between pre and postmenopausal women. Main results are 1) reviews not applicable to primary care settings – more research is needed. 2) for biomarkers i) HE4 at the threshold of 60-80pMol/L and 130-150pMol/L is recommended in pre and postmenopausal women for low prevalence settings ii) ROMA or LR2 in premenopausal women to replace RMI in secondary/tertiary setting; continue with RMI for postmenopausal women as it shows comparable accuracy to ROMA and LR2.","abstract_html":"Ovarian cancer (OC) has the highest mortality of all gynaecological cancers. A significant contributing factor to the high mortality in OC is delayed diagnosis. Currently, there is no consensus regarding the best test for early diagnosis. A review of existing systematic reviews about symptoms, biochemical markers and US test used alone or in combination for the diagnosis of OC in symptomatic women demonstrated that existing reviews were variable in quality, applicability and limited by poor reporting. I attempted to address these deficiencies in two reviews on the accuracy of biomarkers alone and symptoms, biomarkers or US in combination for the diagnosis of OC in symptomatic women in generalist settings in pre and postmenopausal women separately. My thesis finds key methodological issues, e.g., literature is not applicable to generalist settings as studies included women typical of tertiary healthcare settings, some studies excluded borderline tumours which inflates estimates of sensitivity, important differences exist in test performance between pre and postmenopausal women. Main results are 1) reviews not applicable to primary care settings – more research is needed. 2) for biomarkers i) HE4 at the threshold of 60-80pMol/L and 130-150pMol/L is recommended in pre and postmenopausal women for low prevalence settings ii) ROMA or LR2 in premenopausal women to replace RMI in secondary/tertiary setting; continue with RMI for postmenopausal women as it shows comparable accuracy to ROMA and LR2.","abstract_has_math":false,"creators":["Rai Talapadi, Nirmala"],"institution":"University of Birmingham","degree_name":"d_m_d","degree_level":"d_m_d","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-07","date_published":"2021-07","updated_at":"2026-11-19T09:31:19Z","subjects":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/11145/7/RaiTalapadi2021MD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A11145","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["nihr"]},{"key":"dc:creator","label":"Author","values":["Rai Talapadi, Nirmala"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2021-07-21"]},{"key":"dc:date.issued","label":"Date","values":["2021-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cancer and Genomic Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/11145/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_m_d"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_m_d"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/11145/7/RaiTalapadi2021MD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Ovarian cancer (OC) has the highest mortality of all gynaecological cancers. A significant contributing factor to the high mortality in OC is delayed diagnosis. Currently, there is no consensus regarding the best test for early diagnosis. A review of existing systematic reviews about symptoms, biochemical markers and US test used alone or in combination for the diagnosis of OC in symptomatic women demonstrated that existing reviews were variable in quality, applicability and limited by poor reporting. I attempted to address these deficiencies in two reviews on the accuracy of biomarkers alone and symptoms, biomarkers or US in combination for the diagnosis of OC in symptomatic women in generalist settings in pre and postmenopausal women separately. My thesis finds key methodological issues, e.g., literature is not applicable to generalist settings as studies included women typical of tertiary healthcare settings, some studies excluded borderline tumours which inflates estimates of sensitivity, important differences exist in test performance between pre and postmenopausal women. Main results are 1) reviews not applicable to primary care settings – more research is needed. 2) for biomarkers i) HE4 at the threshold of 60-80pMol/L and 130-150pMol/L is recommended in pre and postmenopausal women for low prevalence settings ii) ROMA or LR2 in premenopausal women to replace RMI in secondary/tertiary setting; continue with RMI for postmenopausal women as it shows comparable accuracy to ROMA and LR2."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Biochemical markers and combination testing for the diagnosis of ovarian cancer in women with symptoms or signs suspicious of ovarian cancer"]}]}],"canonical_facts":{"dc:contributor.sponsor":["nihr"],"dc:creator":["Rai Talapadi, Nirmala"],"dc:date":["2021-07-21"],"dc:date.issued":["2021-07"],"dc:description.abstract":["Ovarian cancer (OC) has the highest mortality of all gynaecological cancers. A significant contributing factor to the high mortality in OC is delayed diagnosis. Currently, there is no consensus regarding the best test for early diagnosis. A review of existing systematic reviews about symptoms, biochemical markers and US test used alone or in combination for the diagnosis of OC in symptomatic women demonstrated that existing reviews were variable in quality, applicability and limited by poor reporting. I attempted to address these deficiencies in two reviews on the accuracy of biomarkers alone and symptoms, biomarkers or US in combination for the diagnosis of OC in symptomatic women in generalist settings in pre and postmenopausal women separately. My thesis finds key methodological issues, e.g., literature is not applicable to generalist settings as studies included women typical of tertiary healthcare settings, some studies excluded borderline tumours which inflates estimates of sensitivity, important differences exist in test performance between pre and postmenopausal women. Main results are 1) reviews not applicable to primary care settings – more research is needed. 2) for biomarkers i) HE4 at the threshold of 60-80pMol/L and 130-150pMol/L is recommended in pre and postmenopausal women for low prevalence settings ii) ROMA or LR2 in premenopausal women to replace RMI in secondary/tertiary setting; continue with RMI for postmenopausal women as it shows comparable accuracy to ROMA and LR2."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/11145/7/RaiTalapadi2021MD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cancer and Genomic Sciences"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/11145/"],"dc:subject":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public"],"dc:title":["Biochemical markers and combination testing for the diagnosis of ovarian cancer in women with symptoms or signs suspicious of ovarian cancer"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_m_d"],"dc:type.qualificationname":["d_m_d"]},"updated_at":"2026-11-19T09:31:19Z"}